Blog
Amgen to cut 350 jobs after acquiring Horizon for $28 billion
Recently, in the aftermath of Amgen’s substantial $27.8 billion acquisition of Horizon, unveiled in December and finalized this month, these ...
Elektrofi lands $20M from Eli Lilly for subcutaneous drug partnership
Eli Lilly is collaborating with Elektrofi, a drug delivery specialist, to explore the potential of Elektrofi’s microparticle formulation technology in ...
Idorsia slashes 300 jobs in R&D amid cost-cutting efforts
The company has announced that it will be reducing its workforce by 300 individuals, with a focus on R&D and ...
Boehringer, Teva, others hit with EU fines for drug-ingredient cartel
Five pharmaceutical companies, including the prominent global firm Boehringer Ingelheim, find themselves in the midst of a regulatory storm, facing ...
Aiolos Bio debuts with $250M and ex-Gyroscope CEO to tackle severe asthma
A striking trend throughout 2023 has been the gravitational pull of significant funding toward promising biotech endeavors. This theme is ...
AxoSim acquires Vyant’s organoid tech for brain disorder research
AxoSim, a New Orleans-based drug discovery biotech, has successfully completed the acquisition of the neuroscience research assets from Vyant Bio’s ...
OrbiMed raises $4.3B for 3 funds to back biotech startups
OrbiMed, a major global financier of biopharmaceutical companies, has successfully amassed $4.3 billion, earmarked for investment in emerging healthcare and ...
BrainStorm cuts 30% staff, eyes ALS cell therapy approval
BrainStorm Cell Therapeutics has chosen an unconventional route in response to its recent setback in securing approval. While the decision ...
Indivior ends Suboxone saga with $385M antitrust deal
Indivior, the manufacturer of Suboxone, has taken a significant step towards closing the chapter on years of antitrust litigation related ...
Moderna, BioNTech face hurdles in cancer vaccine production after COVID success
Moderna and BioNTech, both navigating their post-COVID future while reimagining cancer treatments, have encountered manufacturing hurdles along their respective journeys. ...
Keytruda: Merck’s breakthrough cancer drug with mixed results at ESMO
Merck & Co. made significant strides at this year’s European Society for Medical Oncology (ESMO) congress, presenting a series of ...
BioNTech’s CAR-T/CARVac Combo Shows High Response Rates in Solid Tumors, But Also Higher Toxicity (ESMO 2023)
ESMO 2023: LBA35 BioNTech’s innovative manufacturing process for CAR-T therapy, BNT211, has shown promising results in treating solid tumors. While ...
Dato-DXd Shows Efficacy in Lung Cancer, But Safety Issues Remain (ESMO 2023)
ESMO 2023: LBA12 During the Presidential Symposium at the ESMO Congress 2023 in Madrid, a study revealed that datopotamab deruxtecan, ...
Pfizer Faces Backlash for Raising Price of Covid Drug Paxlovid
Following Pfizer’s announcement to increase the cost of its COVID-19 treatment drug, Paxlovid, for the next year, the AIDS Healthcare ...
Pluvicto Improves Survival in Earlier Prostate Cancer, But Faces Regulatory Hurdles (ESMO 2023)
ESMO 2023: LBA13 Novartis is eagerly advancing its radiotherapy drug, Pluvicto, with aspirations of its potential in earlier prostate cancer ...
Dupixent Fails to Win FDA Approval for Hives Disorder, Needs More Data
Regeneron and Sanofi have faced an unexpected hurdle in their pursuit of regulatory approval for Dupixent, a monoclonal antibody aimed ...
Ambrx’s ARX517 Shows Promising Efficacy and Safety in Advanced Prostate Cancer (ESMO 2023)
ESMO 2023: 1804P As of the data cutoff date in September 2023, the results from the study show that increasing ...
Roche’s $7B Investment Ignites Intense Competition with Merck in the Bowel Disease Market Amid TL1A Feeding Frenzy
Roche has made a substantial move by agreeing to pay Roivant and Pfizer $7.1 billion upfront for regional rights to ...
Merus’ Zeno Shows Higher Response Rates in NRG1+ Pancreatic and Lung Cancers (ESMO 2023)
ESMO 2023: 1618P Currently, Ipsen’s Onivyde is the standard of care, but it offers only a 7% chance of response ...
Merck Drops Two Cancer ADCs from Kelun Deal, Focuses on Daiichi Sankyo
Merck & Co. is refining its strategy in the realm of antibody-drug conjugates (ADCs). Shortly after a $4 billion acquisition ...
Imfinzi and Lynparza Combo Improves Survival in Endometrial Cancer Trial (ESMO 2023)
ESMO 2023: LBA41 AstraZeneca is exploring a potentially powerful approach in the fight against endometrial cancer, suggesting that combining their ...
Cabometyx Shows Dramatic Benefits in Advanced Neuroendocrine Tumors (ESMO 2023)
ESMO 2023: LBA53 Exelixis made headlines last month when its Cabometyx exceeded expectations in the treatment of neuroendocrine tumors (NETs), ...
Padcev-Keytruda Combo Doubles Survival in First-Line Bladder Cancer Trial (ESMO 2023)
ESMO 2023: LBA6 Exciting results from the EV-302 phase 3 trial suggest that the partnership between Seagen and Astellas’ antibody-drug ...
Opdivo Beats Chemo in First-Line Bladder Cancer, But Keytruda-Padcev Combo Looms Large (ESMO 2023)
ESMO 2023: LBA7 Bladder cancer has presented a unique challenge for immunotherapies, with Bristol Myers Squibb’s Opdivo making strides, but ...
Lumakras-Vectibix combo outperforms standard therapy in KRAS G12C-mutated colorectal cancer (ESMO 2023)
ESMO 2023: LBA10 Nevertheless, a shadow has been cast over the KRAS inhibitor due to recent criticisms by FDA advisors. ...
Lilly Unveils Exciting Phase III Showdown: Retevmo vs. Keytruda & Chemotherapy in RET Fusion-Positive NSCLC
ESMO 2023: LBA4 RET fusion is found in about 1-2% of patients with non-small cell lung cancer. Retevmo, a highly ...
Phase III ALINA study shows Alecensa’s superior disease-free survival benefit in early-stage lung cancer patients
ESMO 2023: LBA2 About 4-5% of NSCLC cases are identified with ALK rearrangements. In 2015, Alecensa (alectinib) received accelerated approval ...
A novel combination therapy of garsorasib and cetuximab for KRAS G12C mutated colorectal cancer patients
D‐1553 is a small-molecule inhibitor designed to selectively target KRAS G12C and is currently undergoing Phase II clinical trials. It ...
Combination of Osimertinib and Chemotherapy Enhances Brain Control in Advanced EGFR-Mutated Lung Cancer: Results from FLAURA2 Trial
ESMO: LBA68 EGFR mutations are found in 10%-15% of non-small cell lung cancer (NSCLC) cases among European and Caucasian populations. ...
Positive Interim Results from Global Phase III MATTERHORN Study: Imfinzi plus FLOT Demonstrates Clinically Meaningful Improvement in Key Secondary Endpoint (ESMO 2023)
ESMO 2023: LBA73 The results of a MATTERHORN trial was presented in ESMO 2023. The trial tested the effect of ...
